#Singapore #oncology #Emerald Clinical #Luke Gill

Emerald Clinical Trials Welcomes Luke Gill as New Vice President of Oncology

Emerald Clinical Trials, a prominent player in the global clinical research organization (CRO) sector, has recently made headlines with the announcement of Luke Gill, MSc, MBA, being appointed as the new Vice President and Global Head of Oncology and Medical Scientific Affairs. This significant move is part of Emerald's ongoing commitment to bolstering its oncology research and development capabilities, emphasizing the organization's dedication to advancing innovative medical solutions worldwide.

Luke Gill brings an impressive background to his new role. With over 25 years of substantial experience in oncology drug development and clinical operations, he has demonstrated exceptional leadership throughout his career in various notable biotech firms and CROs. Luke's credentials include successful management of oncology programs from early-stage development, through pivotal Phase III trials and regulatory approvals. His expertise in navigating complex clinical operations and strategic partnerships has been instrumental in the successful delivery of innovative oncology therapies.

Before joining Emerald, Gill held several senior executive positions across multiple regions, where he was responsible for overseeing substantial oncology portfolios and forming strategic alliances with key pharmaceutical companies. His educational background, with a Master’s degree in Neuro and Molecular Pharmacology combined with an MBA, equips him with a unique blend of scientific knowledge and business acumen. This dual expertise will be invaluable as Emerald continues to scale its global oncology portfolio.

Glenn Kerkhof, CEO of Emerald Clinical Trials, expressed great enthusiasm about Gill’s appointment, stating, "Luke's appointment marks a pivotal step in Emerald's growth strategy. His proven ability to integrate scientific insights with operational excellence will fortify our alliances and enhance our service delivery for biotech and pharmaceutical clients worldwide."

In his new position, Luke Gill will spearhead the expansion of Emerald’s oncology initiatives, collaborating closely with various teams, including clinical, medical, regulatory, and business development. His leadership is expected to usher in an era of high-impact program execution, ultimately aimed at delivering superior results for patients and healthcare partners alike.

Reflecting on his excitement to be part of Emerald’s journey, Gill stated, "Joining Emerald at this crucial juncture is thrilling. We are united in our commitment to advancing innovative oncology therapies with agility, integrity, and precision. Together, we aim to contribute meaningful progress for patients and partners across the globe."

Emerald Clinical Trials stands as a distinguished entity in the clinical research arena, catering to over 100 biotech companies and six of the top ten pharmaceutical giants worldwide. Headquartered in Singapore, the organization prides itself on operational excellence and scientific precision, providing comprehensive clinical trial services across all phases. As it embarks on this new chapter with Luke Gill at the helm, Emerald Clinical Trials is poised for continued success in the ever-evolving landscape of oncology research.

For additional information on Emerald Clinical Trials and its pioneering initiatives, visit www.emeraldclinical.com.